Commitments to expanded global access for COVID-19 diagnostics, therapeutics, and vaccines.
Sep 30, 2020
COVID-19’s existence anywhere poses a threat to communities everywhere. The health, social, and economic impacts can only be addressed through the collective actions of stakeholders across private, public, and philanthropic sectors in partnership with civil society. As organizations dedicated to improving and protecting global health, with our varied skills, roles, and resources, we remain committed to doing our part in ending this pandemic worldwide. Earlier this year AstraZeneca; Bayer; bioMérieux; Boehringer Ingelheim; Bristol Myers Squibb; Eisai; Eli Lilly; Gilead; GSK; Johnson & Johnson; Merck & Co. (known as MSD outside the U.S. and Canada); Merck KGaA, Darmstadt, Germany; Novartis; Pfizer; Roche; and Sanofi together with the Bill & Melinda Gates Foundation each pledged ourselves to the fight against COVID-19.
Collectively, we have launched the most expansive and ambitious pandemic R&D response effort in history, with the promise of a range of interventions that can help end the pandemic. Creating these innovations is not enough, however. Through partnerships with other stakeholders we are committed to ensuring global access to diagnostics, therapeutics, and vaccines that will help to accelerate the end of the pandemic. To accomplish this critical goal, we will:
Access to interventions to fight COVID-19 on a global scale requires financial resources, assets, infrastructure, and jurisdictional support and collaboration beyond the capacity or role of the signatories to this commitment. We therefore call on governments, multilateral institutions, companies, NGOs, and others to build on our commitments and efforts already underway to:
The world’s extraordinary situation requires unprecedented collaboration across every part of society. To date, we as life science and philanthropic organizations have risen to this challenge and recognize the need to push further. The commitments above will save lives only if partners across the entire development-to-deployment pathway work together to guarantee products reach the people who need them. The ACT-Accelerator offers a forum for collaboration and action, and the global community must collectively mobilize the resources partners have identified as critical to ending this pandemic for communities everywhere. By aligning those resources with the commitments above, we believe we will not only enable a faster path out of the current COVID-19 crisis but will also lay the foundation for a strong pandemic preparedness ecosystem the next time a pandemic arises.
"This pandemic will go down as one of the defining moments of our time, and no one - regardless of their country, their income, or anything else - should have to worry about whether they will have access to the care and innovation that could help them and their loved ones combat COVID-19. This is also a defining moment for the life sciences industry - a moment for a new kind of leadership - and with this agreement, we’ve committed to collectively pursuing a healthier, more equitable future for the good of mankind."
Vas Narasimhan, CEO of Novartis
To read more Press Release articles, click here.